Indiana University Dermatology Clinical Trials

Vitiligo is an autoimmune disease that causes the immune system to destroy pigment-producing skin cells, resulting in white patches. Current dermatology clinical trials in Indiana include a trial of a study drug for non-segmental vitiligo (NSV). Participants will receive either the study drug or a placebo for 48 weeks (about 11 months), followed by the study drug for 112 weeks (about 2 years).

Additional trials are examining other treatments for NSV. This second study drug is under study for its effectiveness, and another trial evaluates a third study drug. In the research study, participants will take the medicine or a placebo and undergo extensive monitoring over 26 months (about 2 years) through regular visits and various medical tests to assess the treatment’s safety and impact.

Palmoplantar Keratoderma (PPK) is a group of rare genetic disorders characterized by the thickening of the skin on the palms of the hands and the soles of the feet. This condition can cause painful fissures and significantly impact daily activities. Current clinical trials in Indiana are exploring innovative treatments for PPK, focusing on both reducing the thickness of the skin and improving the quality of life for patients.

Participants in these trials will receive either the investigational drug or a placebo over a period of 48 weeks (about 11 months), followed by extended monitoring to assess long-term effectiveness and safety.

Additional studies are underway to evaluate other potential therapies for PPK. In one study, a second investigational drug is being tested for its effectiveness, while another trial is evaluating a third promising treatment. Participants in these studies will undergo rigorous testing and monitoring over 26 months (about 2 years) to determine the treatment's safety and impact.